Regulation of Metabolic Activity by p53
Open accessThe DOI matches its Crossref record; 141 of the 144 references it cites were found in a registry or an index.
Abstract
Metabolic reprogramming in cancer cells is controlled by the activation of multiple oncogenic signalling pathways in order to promote macromolecule biosynthesis during rapid proliferation. Cancer cells also need to adapt their metabolism to survive and multiply under the metabolically compromised conditions provided by the tumour microenvironment. The tumour suppressor p53 interacts with the metabolic network at multiple nodes, mostly to reduce anabolic metabolism and promote preservation of cellular energy under conditions of nutrient restriction. Inactivation of this tumour suppressor by deletion or mutation is a frequent event in human cancer. While loss of p53 function lifts an important barrier to cancer development by deleting cell cycle and apoptosis checkpoints, it also removes a crucial regulatory mechanism and can render cancer cells highly sensitive to metabolic perturbation. In this review, we will summarise the major concepts of metabolic regulation by p53 and explore how this knowledge can be used to selectively target p53 deficient cancer cells in the context of the tumour microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, dietary restriction of serine‐glycine is beneficial in tumors lacking p53 because of their inability to counteract reactive oxygen species (ROS)‐associated oxidative stress [241, 242].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [242]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Increasing evidence indicates that p53 also regulates important functions of the immune system, which is especially relevant in cancer [121].”
BackgroundFerroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691 · cited 2×
“This limits the availability of cysteine for GSH synthesis, leading to the accumulation of lipid peroxides and induction of ferroptosis, an iron-dependent form of cell death [89].”
BackgroundUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · cited 1×
“However, it is now established that ATP production is not a rate-limiting process for cell proliferation and that increased glucose uptake allows cancer cells to generate glycolytic intermediates for essential biosynthetic processes, such as the synthesis of riboses for nucleotide biosynthesis [33].”
Backgroundp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 7×
“downregulation of SLC7A11 is an essential part of the tumour suppressor function of p53 [88].”
BackgroundInfluentialMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · cited 1×
“This was demonstrated for cancers in which high glucose uptake was induced by over-expression of hexokinase 2 (HK2) or the MYC oncogene [131].”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 2×
“activate the expression of its negative regulator MDM2, mutant p53 protein is stabilised [25] and can”
BackgroundMetabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“One of the hallmarks of cancer is the altered metabolic activity of cancer cells [31] and many cancer cells rely on glycolysis as the predominant source of ATP production, even in the presence of oxygen.”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“However, strong or sustained activation of p53 leads to the induction of apoptotic cell death by upregulating PUMA, NOXA or BAX [15,16] or senescence by upregulation of p21, thereby providing a barrier towards cell transformation and tumour development [2,8].”
BackgroundA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500 · cited 1×
“Activation of p53 by DNA damage or other stresses induces the expression of genes encoding pro-oxidant enzymes, such as the p53-induced protein PIG3 (TP53I3) [74], the pro-apoptotic factors PUMA (BBC3) [75,76] and NOXA (PMAIP1) [77], and the proline-oxidase (PRODH) [78].”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“In contrast, restoration of p53 expression in sarcomas or in a mosaic mouse model of liver cancer resulted in the induction of senescence in cancer cells and activation of the innate immune response by inflammatory cytokines [127,128].”
BackgroundT antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394 · cited 1×
“TP53 was identified in 1979 [1] and was initially believed to be a proto-oncogene, due to the high frequency of point mutations found in cancers (reviewed in [2]).”
BackgroundPUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · cited 1×
“Activation of p53 by DNA damage or other stresses induces the expression of genes encoding pro-oxidant enzymes, such as the p53-induced protein PIG3 (TP53I3) [74], the pro-apoptotic factors PUMA (BBC3) [75,76] and NOXA (PMAIP1) [77], and the proline-oxidase (PRODH) [78].”
BackgroundVousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Cellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123 · cited 1×
“Lipid metabolism is tightly regulated in cancer cells [90,91].”
BackgroundSelf-citationNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112 · cited 1×
“Activation of p53 by DNA damage or other stresses induces the expression of genes encoding pro-oxidant enzymes, such as the p53-induced protein PIG3 (TP53I3) [74], the pro-apoptotic factors PUMA (BBC3) [75,76] and NOXA (PMAIP1) [77], and the proline-oxidase (PRODH) [78].”
BackgroundDirect Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“However, strong or sustained activation of p53 leads to the induction of apoptotic cell death by upregulating PUMA, NOXA or BAX [15,16] or senescence by upregulation of p21, thereby providing a barrier towards cell transformation and tumour development [2,8].”
BackgroundActivation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 2×
“As a consequence, G6P is redirected into the PPP to support enhanced ribose production for nucleotide synthesis during DNA repair [40,41].”
BackgroundThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987 · cited 1×
“However, 10 years later it was realised that loss or mutation of TP53 inactivates one of the most important tumour suppressors [3,4].”
BackgroundThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 2×
“Interestingly, tumour clearance in response to acute restoration of p53 in lymphomas is associated with induction of apoptosis [126,127].”
BackgroundThe multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651 · cited 2×
“Many cancers show enhanced rates of fatty acid biosynthesis as part of their overall increase in anabolic metabolism during rapid proliferation [92].”
BackgroundSelf-citationp53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650 · cited 2×
“Increased expression of factors that promote mitochondrial respiration can also enhance oxidative stress in response to p53 activation [66].”
BackgroundMuller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · cited 2×
“exert additional tumour promoting functions [26].”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619 · cited 1×
“It has been shown, for example, that glucose deprivation triggers cell cycle arrest by inducing AMPK-dependent phosphorylation and activation of p53 [117].”
BackgroundKruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 2×
“In response to DNA damage or oncogenic stress, p53 is activated through post-translational modifications, such as acetylation or phosphorylation, which prevent its interaction with MDM2 and lead to an increased stability of p53 [11,12].”
BackgroundControl of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438 · cited 1×
“It has been shown that p53 blocks tumour angiogenesis by inducing the expression of thrombospondin 1 (TSP1) in fibroblasts derived from Li-Fraumeni patients, a hereditary disorder caused by germline mutation of p53 [118].”
BackgroundSREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413 · cited 1×
“a family of basic helix-loop helix transcription factors that control the expression of most enzymes involved in fatty acid and cholesterol biosynthesis [98,99] (Figure 3).”
BackgroundSelf-citationFueling Immunity: Insights into Metabolism and Lymphocyte Function
Pearce, E. L., Poffenberger, M. C., Chang, C.-H., & Jones, R. G. (2013) · Science · doi:10.1126/science.1242454 · Cited by 1,363 · cited 1×
“Effective tumour clearance by the immune system requires the function of cytotoxic T-cells and there is increasing evidence that T-cells undergo substantial metabolic reprogramming during activation to support their function [130].”
BackgroundSantos, C. R., & Schulze, A. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08644.x · Cited by 1,335
Self-citationp53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327 · cited 1×
“However, strong or sustained activation of p53 leads to the induction of apoptotic cell death by upregulating PUMA, NOXA or BAX [15,16] or senescence by upregulation of p21, thereby providing a barrier towards cell transformation and tumour development [2,8].”
Backgroundp53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 1×
“p53 increases the expression of antioxidant systems, for example the stress-inducible sestrin proteins [81,82] or the p53-inducible nuclear protein 1 (TP53INP1) [83].”
BackgroundCancer metabolism: fatty acid oxidation in the limelight
Carracedo, A., Cantley, L. C., & Pandolfi, P. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3483 · Cited by 1,324 · cited 1×
“Some cancers also increase the degradation of fatty acids, which can contribute to ATP production via mitochondrial β-oxidation or supply metabolic intermediates, including acetyl-CoA or citrate [93].”
BackgroundLowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309 · cited 1×
“to DNA damage and prevents apoptosis or senescence in cancer cells [27-29].”
BackgroundPUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,280 · cited 1×
“Activation of p53 by DNA damage or other stresses induces the expression of genes encoding pro-oxidant enzymes, such as the p53-induced protein PIG3 (TP53I3) [74], the pro-apoptotic factors PUMA (BBC3) [75,76] and NOXA (PMAIP1) [77], and the proline-oxidase (PRODH) [78].”
BackgroundMutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247 · cited 1×
“Through this mechanism, mutant p53 can promote cell motility and invasion, which are hallmarks of cell transformation and tumour development [105].”
BackgroundmTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Peterson, T. R., Sengupta, S. S., Harris, T. E., Carmack, A. E., Kang, S. A., Balderas, E., Guertin, D. A., Madden, K. L., Carpenter, A. E., Finck, B. N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.034 · Cited by 1,229 · cited 2×
“While SREBP is activated through the canonical pathway by low cellular sterol levels, mTORC1 dependent activation involves multiple different mechanisms (reviewed in [96]), including enhanced ER/Golgi translocation [100] and control of its sub-nuclear localisation by the phosphatidate phosphatase lipin 1 (LPIN1) [101].”
BackgroundAnastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190 · cited 1×
“Inhibition of PKM2 in the absence of serine results in the accumulation of metabolic intermediates that can be used for de novo serine biosynthesis [55,56] and also promotes the activity of the oxidative branch of the PPP for NADPH regeneration and antioxidant production [57].”
BackgroundThe antioxidant function of the p53 tumor suppressor
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,121 · cited 2×
“Furthermore, p53 can be activated by inhibition of the PPP, indicating a negative feedback loop to restore PPP activity through p53 and TIGAR to protect cells from ROS-associated damage [43,44].”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“Another strategy is to restore structure of DNA binding domain of mutant p53 by compounds that act as molecular chaperones [134].”
BackgroundSerine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007 · cited 9×
“Increased GLS2 expression enhances mitochondrial respiration, ATP generation and glutathione (GSH) production and decreases cellular ROS levels [72,73], discussed in more detail below.”
BackgroundInfluentialSerine and one-carbon metabolism in cancer
Yang, M., & Vousden, K. H. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.81 · Cited by 992 · cited 1×
“The serine biosynthesis pathway also intersects with the folate and methionine cycles, which produce methyl-groups for nucleotide synthesis as well as for histone and DNA methylation [60].”
BackgroundBuzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923 · cited 8×
“As outlined above, p53 reduces global cellular anabolic metabolism by limiting NADPH production, which is an essential cofactor for many biosynthetic reactions including fatty acid synthesis. p53 also induces the AMP activated protein kinase (AMPK), which blocks fatty acid biosynthesis by phosphorylation of acetyl-CoA…”
BackgroundMethodInfluentialTumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912 · cited 2×
“Importantly, it has been shown that the regulation of metabolic activity is essential to the tumour suppressive function of p53 [30].”
BackgroundMutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · cited 2×
“and increasing the expression of SREBP2 target genes [104].”
BackgroundGlutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
Hu, W., Zhang, C., Wu, R., Sun, Y., Levine, A., & Feng, Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001006107 · Cited by 862 · cited 1×
“Increased GLS2 expression enhances mitochondrial respiration, ATP generation and glutathione (GSH) production and decreases cellular ROS levels [72,73], discussed in more detail below.”
BackgroundDatabase of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796 · cited 1×
“Furthermore, mutant p53 has been also shown to be an important regulator in migration and invasion by affecting signalling by integrins and the EGF receptor (EGFR) [116].”
Backgroundp53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase
Jiang, P., Du, W., Wang, X., Mancuso, A., Gao, X., Wu, M., & Yang, X. (2011) · Nature Cell Biology · doi:10.1038/ncb2172 · Cited by 795 · cited 3×
“As already mentioned above, inhibition of G6PD activity by p53 limits NADPH production by the oxidative PPP [51].”
BackgroundSubbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., & Dannenberg, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21875 · Cited by 786 · cited 1×
“Conversely, p53 reduces the expression of pro-oxidant genes, such as nitric oxide synthase (NOS2) [79] or cyclooxygenase 2 (COX2) [80].”
BackgroundNon-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 2×
“During chronic liver damage, ablation of a p53-dependent induction of senescence in hepatic stellate cells can promote transformation and tumour formation by adjacent epithelial cells, confirming non-cell autonomous tumour suppressor functions of p53 [113].”
BackgroundRegeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD
Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V., & Chumakov, P. M. (2004) · Science · doi:10.1126/science.1095569 · Cited by 731 · cited 1×
“p53 increases the expression of antioxidant systems, for example the stress-inducible sestrin proteins [81,82] or the p53-inducible nuclear protein 1 (TP53INP1) [83].”
BackgroundThe Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0846 · Cited by 726 · cited 1×
“Wild type p53 reduces the expression of the glucose transporters GLUT1 and GLUT4 through direct transcriptional repression [34].”
BackgroundDrugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719 · cited 1×
“Therefore, restoring p53 function in an established tumour should provide a major therapeutic benefit [132].”
BackgroundSuzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705 · cited 1×
“Increased GLS2 expression enhances mitochondrial respiration, ATP generation and glutathione (GSH) production and decreases cellular ROS levels [72,73], discussed in more detail below.”
BackgroundWild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 692 · cited 1×
“However, 10 years later it was realised that loss or mutation of TP53 inactivates one of the most important tumour suppressors [3,4].”
BackgroundSerine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661 · cited 1×
“Inhibition of PKM2 in the absence of serine results in the accumulation of metabolic intermediates that can be used for de novo serine biosynthesis [55,56] and also promotes the activity of the oxidative branch of the PPP for NADPH regeneration and antioxidant production [57].”
BackgroundInflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
Glycolytic Enzymes Can Modulate Cellular Life Span
Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., & Beach, D. (2005) · Cancer Research · doi:10.1158/0008-5472.177.65.1 · Cited by 647 · cited 3×
“Glycolysis also provides essential intermediates for biosynthetic pathways, including the synthesis of serine and glycine. p53 drives ubiquitination and inactivation of phosphoglycerate mutase 1 (PGAM1) [52], an enzyme of the glycolytic pathway that converts 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG).”
BackgroundInfluentialDirect Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638 · cited 1×
“Furthermore, the p53 target p21 directly interacts with the nuclear factor NRF2 (NFE2L2), leading to upregulation of the antioxidant response [84].”
Backgroundp53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
Kawauchi, K., Araki, K., Tobiume, K., & Tanaka, N. (2008) · Nature Cell Biology · doi:10.1038/ncb1724 · Cited by 637 · cited 2×
“Furthermore, p53 blocks the expression of GLUT3 by interfering with the activity of IκB kinases α and β (IKKα/β) and inhibiting nuclear factor kappa B1 (NF-κB) [35].”
BackgroundFeng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633 · cited 7×
“As outlined above, p53 reduces global cellular anabolic metabolism by limiting NADPH production, which is an essential cofactor for many biosynthetic reactions including fatty acid synthesis. p53 also induces the AMP activated protein kinase (AMPK), which blocks fatty acid biosynthesis by phosphorylation of acetyl-CoA…”
BackgroundMethodInfluentialA key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence
Kaplon, J., Zheng, L., Meissl, K., Chaneton, B., Selivanov, V. A., Mackay, G., van der Burg, S. H., Verdegaal, E. M. E., Cascante, M., Shlomi, T., et al. (2013) · Nature · doi:10.1038/nature12154 · Cited by 633 · cited 2×
“In addition, oncogene induced senescence leads to the activation of PDH and increased oxidation of pyruvate by the TCA cycle [129].”
Background�ber den Stoffwechsel der Carcinomzelle
Warburg, O. (1924) · Die Naturwissenschaften · doi:10.1007/bf01504608 · Cited by 631
Modulating the therapeutic response of tumours to dietary serine and glycine starvation
Maddocks, O. D. K., Athineos, D., Cheung, E. C., Lee, P., Zhang, T., van den Broek, N. J. F., Mackay, G. M., Labuschagne, C. F., Gay, D., Kruiswijk, F., et al. (2017) · Nature · doi:10.1038/nature22056 · Cited by 603 · cited 1×
“However, in a genetic model of pancreatic cancer driven by activation of Kras together with either loss or mutation of p53, combined removal of serine and glycine from the diet had no effect on tumour growth [62].”
BackgroundModeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“Interestingly, tumour clearance in response to acute restoration of p53 in lymphomas is associated with induction of apoptosis [126,127].”
BackgroundA Call for Systematic Research on Solute Carriers
César-Razquin, A., Snijder, B., Frappier-Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R. A., Hepworth, D., Hediger, M. A., Edwards, A. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.022 · Cited by 580 · cited 1×
“In this context, large scale screening approaches that investigate the contribution of nutrient transporters could be particularly useful [136].”
BackgroundSerine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells
Labuschagne, C. F., van den Broek, N. J. F., Mackay, G. M., Vousden, K. H., & Maddocks, O. D. K. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.045 · Cited by 576 · cited 1×
“In the absence of exogenous serine, glycine is converted into serine by consuming one-carbon units and thus nucleotide synthesis is inhibited [58].”
BackgroundHussain, S. P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W. P., Shields, P. G., Ham, A. L., Swenberg, J. A., Marrogi, A. J., et al. (2000) · PubMed · Cited by 557
Bourdon, A., Minai, L., Serre, V., Jais, J.-P., Sarzi, E., Aubert, S., Chrétien, D., de Lonlay, P., Paquis-Flucklinger, V., Arakawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng2040 · Cited by 531 · cited 1×
“It has been shown that p53 regulates mitochondrial DNA copy number and mitochondrial mass [63,64] and promotes oxidative phosphorylation via transcriptional activation of p53R2 (RRM2B), a subunit of ribonucleotide reductase [64,65].”
BackgroundCoping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493 · cited 1×
“For example, p53 induces the degradation of the EMT transcription factor Slug (SNAI2) via MDM2 in non-small cell lung cancer [115].”
BackgroundReciprocal regulation of p53 and malic enzymes modulates metabolism and senescence
Jiang, P., Du, W., Mancuso, A., Wellen, K. E., & Yang, X. (2013) · Nature · doi:10.1038/nature11776 · Cited by 491 · cited 2×
“enzymes 1 and 2 (ME1 and ME2), which also contribute to cellular NADPH production [87].”
BackgroundZaugg, K., Yao, Y., Reilly, P. T., Kannan, K., Kiarash, R., Mason, J., Huang, P., Sawyer, S. K., Fuerth, B., Faubert, B., et al. (2011) · Genes & Development · doi:10.1101/gad.1987211 · Cited by 490 · cited 2×
“Likewise, it was shown that carnitin palmitoyl transferase 1C (CPT1C) is important to compensate for the adverse effects of glucose deprivation and hypoxia by increasing the levels of fatty acid oxidation and ATP production [110].”
BackgroundForrester, K., Ambs, S., Lupold, S. E., Kapust, R. B., Spillare, E. A., Weinberg, W. C., Felley-Bosco, E., Wang, X. W., Geller, D. A., Tzeng, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2442 · Cited by 469 · cited 1×
“Conversely, p53 reduces the expression of pro-oxidant genes, such as nitric oxide synthase (NOS2) [79] or cyclooxygenase 2 (COX2) [80].”
Backgroundp53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454 · cited 2×
“TP53 was identified in 1979 [1] and was initially believed to be a proto-oncogene, due to the high frequency of point mutations found in cancers (reviewed in [2]).”
BackgroundThe p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450 · cited 2×
“In response to DNA damage or oncogenic stress, p53 is activated through post-translational modifications, such as acetylation or phosphorylation, which prevent its interaction with MDM2 and lead to an increased stability of p53 [11,12].”
BackgroundSundqvist, A., Bengoechea-Alonso, M. T., Ye, X., Lukiyanchuk, V., Jin, J., Harper, J. W., & Ericsson, J. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.04.010 · Cited by 443 · cited 1×
“The stability of nuclear SREBP is controlled by ubiquitin-mediated protein degradation through a mechanism involving phosphorylation of SREBP by the glycogen synthase kinases (GSK3) and binding of the F-Box and WD repeat domain containing 7 protein (FBXW7), a subunit of the SCF ubiquitin ligase, to a phosphodegron mot…”
BackgroundRIDER, M. H., BERTRAND, L., VERTOMMEN, D., MICHELS, P. A., ROUSSEAU, G. G., & HUE, L. (2004) · Biochemical Journal · doi:10.1042/bj20040752 · Cited by 440 · cited 10×
“In contrast, loss of p53 increases the expression of PFKFB4, which also reduces the production of Fru-2,6-BP and promotes pentose phosphate pathway activity in p53 deficient cancer cells.”
BackgroundInfluentialMaddocks, O. D. K., Labuschagne, C. F., Adams, P. D., & Vousden, K. H. (2016) · Molecular Cell · doi:10.1016/j.molcel.2015.12.014 · Cited by 440 · cited 2×
“In addition, in colorectal cancer cells serine-dependent de novo ATP synthesis supports the conversion of methionine to S-adenosyl methionine (SAM), the primary cellular methyl donor [61].”
BackgroundPhosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth
Hitosugi, T., Zhou, L., Elf, S., Fan, J., Kang, H.-B., Seo, J. H., Shan, C., Dai, Q., Zhang, L., Xie, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.020 · Cited by 432 · cited 2×
“the serine biosynthesis pathway, which is allosterically activated by 2PG [53].”
BackgroundParkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A. J., Hu, W., & Feng, Z. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113884108 · Cited by 431 · cited 2×
“ligase complex and regulator of energy metabolism and antioxidant defense [85].”
BackgroundYe, J., Mancuso, A., Tong, X., Ward, P. S., Fan, J., Rabinowitz, J. D., & Thompson, C. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204176109 · Cited by 410 · cited 1×
“Inhibition of PKM2 in the absence of serine results in the accumulation of metabolic intermediates that can be used for de novo serine biosynthesis [55,56] and also promotes the activity of the oxidative branch of the PPP for NADPH regeneration and antioxidant production [57].”
BackgroundAtsumi, T., Chesney, J. A., Metz, C. N., Leng, L., Donnelly, S. C., Makita, Z., Mitchell, R., & Bucala, R. (2002) · PubMed · Cited by 367
Modulation of intracellular ROS levels by TIGAR controls autophagy
Bensaad, K., Cheung, E. C., & Vousden, K. H. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.242 · Cited by 360 · cited 8×
“Increased GLS2 expression enhances mitochondrial respiration, ATP generation and glutathione (GSH) production and decreases cellular ROS levels [72,73], discussed in more detail below.”
BackgroundInfluentialThe regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein
Feng, Z., & Levine, A. J. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.03.004 · Cited by 359 · cited 1×
“In line with its role in blocking anabolic metabolism, p53 decreases fatty acid synthesis but enhances fatty acid degradation [94].”
BackgroundKeeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352 · cited 1×
“The low basal expression of p53 in unstressed cells is maintained by MDM2/HDM2 (mouse/human double minute 2 homolog) and MDM4 (also called MDMX) [10].”
BackgroundLiu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325 · cited 1×
“to DNA damage and prevents apoptosis or senescence in cancer cells [27-29].”
BackgroundWhat has senescence got to do with cancer?
Dimri, G. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.025 · Cited by 313 · cited 1×
“to DNA damage and prevents apoptosis or senescence in cancer cells [27-29].”
BackgroundThe CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1
Han, J., Li, E., Chen, L., Zhang, Y., Wei, F., Liu, J., Deng, H., & Wang, Y. (2015) · Nature · doi:10.1038/nature14557 · Cited by 312 · cited 1×
“While SREBP is activated through the canonical pathway by low cellular sterol levels, mTORC1 dependent activation involves multiple different mechanisms (reviewed in [96]), including enhanced ER/Golgi translocation [100] and control of its sub-nuclear localisation by the phosphatidate phosphatase lipin 1 (LPIN1) [101].”
BackgroundSchwitalla, S., Ziegler, P. K., Horst, D., Becker, V., Kerle, I., Begus-Nahrmann, Y., Lechel, A., Rudolph, K. L., Langer, R., Slotta-Huspenina, J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.014 · Cited by 296 · cited 2×
“For example, p53 induces the degradation of the EMT transcription factor Slug (SNAI2) via MDM2 in non-small cell lung cancer [115].”
BackgroundHuman Gene Mutation Database?A biomedical information and research resource
Krawczak, M., Ball, E. V., Fenton, I., Stenson, P. D., Abeysinghe, S., Thomas, N., & Cooper, D. N. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<45::aid-humu10>3.0.co;2-t · Cited by 273
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271 · cited 2×
“region of the TP53 gene, but this varies among different tumour types [17,18].”
BackgroundRos, S., & Schulze, A. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-8 · Cited by 269 · cited 10×
“In contrast, loss of p53 increases the expression of PFKFB4, which also reduces the production of Fru-2,6-BP and promotes pentose phosphate pathway activity in p53 deficient cancer cells.”
BackgroundSelf-citationThe p53 protein is an unusually shaped tetramer that binds directly to DNA.
Friedman, P. N., Chen, X., Bargonetti, J., & Prives, C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3319 · Cited by 264 · cited 2×
“Importantly, as p53 functions as a tetramer [24], the presence of mutant p53 in cancer cells has a dominant negative effect on wild type p53 function even in heterozygous cells.”
Backgroundp53 is a suppressor of inflammatory response in mice
Komarova, E. A., Krivokrysenko, V., Wang, K., Neznanov, N., Chernov, M. V., Komarov, P. G., Brennan, M., Golovkina, T. V., Rokhlin, O., Kuprash, D. V., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3213fje · Cited by 247
Zhao, Y., Chaiswing, L., Velez, J. M., Batinic-Haberle, I., Colburn, N. H., Oberley, T. D., & St. Clair, D. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3835 · Cited by 245 · cited 2×
“for the removal of superoxide from the mitochondrial matrix [86].”
Backgroundp53 Negatively Regulates Transcription of the Pyruvate Dehydrogenase Kinase Pdk2
Contractor, T., & Harris, C. R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1215 · Cited by 245 · cited 2×
“p53 transcriptionally represses pyruvate dehydrogenase kinase-2 (PDK2), which phosphorylates and inhibits the pyruvate dehydrogenase (PDH) activity [69].”
Backgroundp53 alterations in human cancer: more questions than answers
Soussi, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210280 · Cited by 232
Glucose Catabolism in Cancer Cells
Mathupala, S. P., Heese, C., & Pedersen, P. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22776 · Cited by 231 · cited 1×
“Similarly, the promoter of the gene coding for hexokinase 2 (HK2) contains several p53 binding sites and is repressed by wild type p53 [36].”
BackgroundNovel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents
Thurnher, M., Nussbaumer, O., & Gruenbacher, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0489 · Cited by 224 · cited 1×
“In addition, statins, a class of cholesterol-lowering drugs that block a key enzyme of the mevalonate pathway, could be particularly efficient in p53 mutant cancers [138].”
BackgroundHot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221 · cited 2×
“protein, leading to reduced binding of p53 to the promoters of its target genes [23].”
Backgroundp53 Activation in Adipocytes of Obese Mice
Yahagi, N., Shimano, H., Matsuzaka, T., Najima, Y., Sekiya, M., Nakagawa, Y., Ide, T., Tomita, S., Okazaki, H., Tamura, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302364200 · Cited by 220 · cited 2×
“increasing the expression of SREBP1c [103].”
BackgroundPGC-1 coactivators in the control of energy metabolism
Liu, C., & Lin, J. D. (2011) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr007 · Cited by 210 · cited 1×
“Considering that PGC1A also controls the expression of genes involved in mitochondrial oxidative metabolism [109], the interaction between p53 and PGC1α could also promote fatty acid oxidation.”
BackgroundBoidot, R., Végran, F., Meulle, A., Le Breton, A., Dessy, C., Sonveaux, P., Lizard-Nacol, S., & Feron, O. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2474 · Cited by 203 · cited 1×
“Moreover, p53 suppresses the expression of the lactate/proton symporter monocarboxylate transporter 1 (MCT1), thereby reducing the ability of cells to regenerate NAD+ through the conversion of pyruvate to lactate [70].”
BackgroundRos, S., Santos, C. R., Moco, S., Baenke, F., Kelly, G., Howell, M., Zamboni, N., & Schulze, A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0234 · Cited by 201 · cited 1×
“PFKFB4 was previously shown to be essential for the survival of prostate cancer cells [49] and glioma stem-like cells [50].”
BackgroundSelf-citationRegulation of AIF expression by p53
Stambolsky, P., Weisz, L., Shats, I., Klein, Y., Goldfinger, N., Oren, M., & Rotter, V (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401965 · Cited by 194 · cited 3×
“HK2 = hexokinase 2; G6P = glucose-6-phosphate; TIGAR = TP53 induced glycolysis regulatory phosphatase; Fru-2,6-BP = fructose-2,6-bisphosphate; PFKFB4 = phosphofructokinase-2/fructose-2-bisphosphatases; PGAM = phosphoglycerate mutase; MCT1 = monocarboxylate transporter 1; SCO2 = synthesis of cytochrome c oxidase assemb…”
BackgroundROS-Mediated p53 Induction of Lpin1 Regulates Fatty Acid Oxidation in Response to Nutritional Stress
Assaily, W., Rubinger, D. A., Wheaton, K., Lin, Y., Ma, W., Xuan, W., Brown-Endres, L., Tsuchihara, K., Mak, T. W., & Benchimol, S. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.038 · Cited by 192 · cited 1×
“In contrast to its negative effect on fatty acid synthesis, p53 increases fatty acid β-oxidation, for example after nutrient deprivation via induction of AMPK [106] or through induction of LPIN1 expression in response to glucose deprivation, oxidative stress or DNA damage [107].”
BackgroundLebedeva, M. A., Eaton, J. S., & Shadel, G. S. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.01.004 · Cited by 183 · cited 1×
“It has been shown that p53 regulates mitochondrial DNA copy number and mitochondrial mass [63,64] and promotes oxidative phosphorylation via transcriptional activation of p53R2 (RRM2B), a subunit of ribonucleotide reductase [64,65].”
BackgroundPGC-1α, a Key Modulator of p53, Promotes Cell Survival upon Metabolic Stress
Sen, N., Satija, Y. K., & Das, S. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.044 · Cited by 166 · cited 1×
“Moreover, in response to glucose deprivation, p53 binds to the PPARG coactivator 1 alpha (PGC1A) and induces the expression of genes promoting cell cycle arrest and ROS clearance [108].”
BackgroundCaught in the cross fire: p53 in inflammation
Cooks, T., Harris, C. C., & Oren, M. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu134 · Cited by 162
A pivotal role for p53: balancing aerobic respiration and glycolysis
Ma, W., Sung, H. J., Park, J., Matoba, S., & Hwang, P. M. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9083-0 · Cited by 160 · cited 1×
“As a consequence, cells that lack p53 generate less ATP through oxidative phosphorylation compared to p53 proficient cells [71].”
BackgroundThe p53-induced Gene-6 (Proline Oxidase) Mediates Apoptosis through a Calcineurin-dependent Pathway
Rivera, A., & Maxwell, S. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504852200 · Cited by 160 · cited 1×
“Activation of p53 by DNA damage or other stresses induces the expression of genes encoding pro-oxidant enzymes, such as the p53-induced protein PIG3 (TP53I3) [74], the pro-apoptotic factors PUMA (BBC3) [75,76] and NOXA (PMAIP1) [77], and the proline-oxidase (PRODH) [78].”
BackgroundGoidts, V., Bageritz, J., Puccio, L., Nakata, S., Zapatka, M., Barbus, S., Toedt, G., Campos, B., Korshunov, A., Momma, S., et al. (2011) · Oncogene · doi:10.1038/onc.2011.490 · Cited by 156 · cited 1×
“PFKFB4 was previously shown to be essential for the survival of prostate cancer cells [49] and glioma stem-like cells [50].”
BackgroundTumor Protein 53–Induced Nuclear Protein 1 Is a Major Mediator of p53 Antioxidant Function
Cano, C. E., Gommeaux, J., Pietri, S., Culcasi, M., Garcia, S., Seux, M., Barelier, S., Vasseur, S., Spoto, R. P., Pébusque, M.-J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2320 · Cited by 151 · cited 2×
“Antioxidant factors that prevent or remove cellular ROS are also modulated by p53. p53 increases the expression of antioxidant systems, for example the stress-inducible sestrin proteins [81,82] or the p53-inducible nuclear protein 1 (TP53INP1) [83].”
Backgroundp53 regulates mtDNA copy number and mitocheckpoint pathway
Singh, K., Kulawiec, M., & Ayyasamy, V. (2009) · Journal of Carcinogenesis · doi:10.4103/1477-3163.50893 · Cited by 137 · cited 1×
“It has been shown that p53 regulates mitochondrial DNA copy number and mitochondrial mass [63,64] and promotes oxidative phosphorylation via transcriptional activation of p53R2 (RRM2B), a subunit of ribonucleotide reductase [64,65].”
BackgroundRegulation of lipid metabolism by p53 – fighting two villains with one sword
Goldstein, I., & Rotter, V. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.007 · Cited by 135 · cited 1×
“Therefore, it can be concluded that metabolic regulation by p53 needs to be studied in the context of the complex interactions within the metabolic network [112].”
BackgroundErratum: Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4288 · Cited by 135
Mitochondrial impairment in p53-deficient human cancer cells
Zhou, S. (2003) · Mutagenesis · doi:10.1093/mutage/18.3.287 · Cited by 124 · cited 1×
“In addition, p53 regulates the COXII subunit of complex IV, which is encoded by the mitochondrial genome, through a post-transcriptional mechanism [68].”
Backgroundp53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway
Ghahremani, M. F., Goossens, S., Nittner, D., Bisteau, X., Bartunkova, S., Zwolińska, A., Hulpiau, P., Haigh, K., Haenebalcke, L., Drogat, B., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.12 · Cited by 119 · cited 1×
“However, in the absence of the retinoblastoma tumour suppressor protein (pRB), p53 can induce angiogenesis by binding to the promoter of the vascular endothelial growth factor (VEGF) gene [120].”
BackgroundStructural and Biochemical Studies of TIGAR (TP53-induced Glycolysis and Apoptosis Regulator)
Li, H., & Jogl, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807821200 · Cited by 117 · cited 1×
“As a consequence, G6P is redirected into the PPP to support enhanced ribose production for nucleotide synthesis during DNA repair [40,41].”
BackgroundInteractions between the tumor suppressor p53 and immune responses
Menendez, D., Shatz, M., & Resnick, M. A. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6386 · Cited by 114
Sanchez-Macedo, N., Feng, J., Faubert, B., Chang, N., Elia, A., Rushing, E. J., Tsuchihara, K., Bungard, D., Berger, S. L., Jones, R. G., et al. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.168 · Cited by 98 · cited 1×
“CPT1C was also identified as a direct transcriptional target of p53 both in vitro and in vivo [111].”
BackgroundWild-type p53 in cancer cells: When a guardian turns into a blackguard
Kim, E. L., Giese, A., & Deppert, W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.030 · Cited by 98 · cited 1×
“Transient cell cycle arrest induced by p53 allows DNA repair and supports genome stability and cell survival [13,14].”
BackgroundThe role of p53 in glucose metabolism
Cheung, E. C., & Vousden, K. H. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.006 · Cited by 97 · cited 1×
“Moreover, TIGAR is required for intestinal regeneration and tumourigenesis [46], but is upregulated in cancer through mechanism independent of p53 or p73 [47], suggesting possible additional functions of this enzyme.”
BackgroundFutamura, M., Kamino, H., Miyamoto, Y., Kitamura, N., Nakamura, Y., Ohnishi, S., Masuda, Y., & Arakawa, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2485 · Cited by 93 · cited 1×
“Likewise, semaphorin 3F (SEMA3F), a direct transcriptional target of p53, was found to inhibit angiogenesis in colon cancer [119].”
BackgroundJin, H.-O., An, S., Lee, H.-C., Woo, S.-H., Seo, S.-K., Choe, T.-B., Yoo, D.-H., Lee, S.-B., Um, H.-D., & Lee, S.-J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.12.014 · Cited by 91 · cited 1×
“Several negative regulators of mTORC1, including the insulin like growth factor binding protein 1 (IGFBP1), the phosphatase and tensin homolog (PTEN), the tuberous sclerosis protein 2 (TSC2) and the DNA damage inducible transcript 4 (DDIT4/REDD1) [95,97] are also transcriptional targets of p53.”
Background6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells
Ros, S., Flöter, J., Kaymak, I., Da Costa, C., Houddane, A., Dubuis, S., Griffiths, B., Mitter, R., Walz, S., Blake, S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.477 · Cited by 83 · cited 17×
“As a consequence, disrupting metabolic control mechanisms that maintain the balance of metabolite flux between glycolysis and PPP should selectively impair the survival of p53 deficient cancer cells and could be a strategy for therapeutic intervention.”
BackgroundSelf-citationRuiz‐Lozano, P., Hixon, M. L., Wagner, M. W., Flores, A. I., Ikawa, S., Baldwin, A. S., Chien, K. R., & Gualberto, A. (1999) · PubMed · Cited by 77
PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant p53
Zache, N., Lambert, J. M. R., Wiman, K. G., & Bykov, V. J. N. (2008) · Analytical Cellular Pathology · doi:10.1155/2008/527939 · Cited by 77
Guo, G., Marrero, L., Rodriguez, P., Del Valle, L., Ochoa, A., & Cui, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3810 · Cited by 69
PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68 · cited 1×
“One of these compounds, PRIMA-1MET (APR-246), has been shown to efficiently inhibit the growth of p53 mutant tumours [135].”
BackgroundGuo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 53 · cited 1×
“Transient cell cycle arrest induced by p53 allows DNA repair and supports genome stability and cell survival [13,14].”
BackgroundGerin, I., Noël, G., Bolsée, J., Haumont, O., SCHAFTINGEN, E. V., & Bommer, G. T. (2014) · Biochemical Journal · doi:10.1042/bj20130841 · Cited by 49 · cited 10×
“In contrast, loss of p53 increases the expression of PFKFB4, which also reduces the production of Fru-2,6-BP and promotes pentose phosphate pathway activity in p53 deficient cancer cells.”
BackgroundInfluentialTrp53 negatively regulates autoimmunity via the STAT3‐Th17 axis
Zhang, S., Zheng, M., Kibe, R., Huang, Y., Marrero, L., Warren, S., Zieske, A. W., Iwakuma, T., Kolls, J. K., & Cui, Y. (2011) · The FASEB Journal · doi:10.1096/fj.10-175299 · Cited by 45
p53- and p73-independent activation of TIGAR expression in vivo
Lee, P., Hock, A. K., Vousden, K. H., & Cheung, E. C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.205 · Cited by 34 · cited 1×
“Moreover, TIGAR is required for intestinal regeneration and tumourigenesis [46], but is upregulated in cancer through mechanism independent of p53 or p73 [47], suggesting possible additional functions of this enzyme.”
BackgroundReactive Oxygen Species-independent Oxidation of Thioredoxin in Hypoxia
Muniyappa, H., Song, S., Mathews, C. K., & Das, K. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.008557 · Cited by 29 · cited 1×
“Furthermore, p53 can be activated by inhibition of the PPP, indicating a negative feedback loop to restore PPP activity through p53 and TIGAR to protect cells from ROS-associated damage [43,44].”
BackgroundOronsky, B. T., Scicinski, J. J., Reid, T. R., Oronsky, A. L., Carter, C. A., Oronsky, N. C., & Cabrales, P. (2016) · PubMed · Cited by 25
Cited by
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
“Several laboratories have also highlighted a major role of p53 in metabolism and showed that p53associated metabolic functions contribute to its tumor suppressive activities [2,3].”
BackgroundTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Control of metabolism by p53 – Cancer and beyond
Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 219
“Activities of p53 that help to maintain mitochondrial health, increase mitochondrial respiration and lower glycolysis have been described [49] and the full gamut of p53-regulated metabolic target genes is discussed in detail in many recent reviews [5, 16, 50, 51] Briefly, p53 represses the expression of several glucos…”
BackgroundMetabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy
Nenkov, M., Ma, Y., Gaßler, N., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126262 · Cited by 218
Metadata
- Authors
- Flöter, J., Kaymak, I., & Schulze, A.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Schulze, Almut
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2017-05-20
- Volume
- 7
- Issue
- 2
- Pages
- 21
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC5487992
- OpenAlex
- W2616453324
- Cited by
- 81
- References
- 144
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 9 · 2022: 11 · 2021: 7 · 2020: 12 · 2019: 12 · 2018: 12 · 2017: 9
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- DFG (FOR2314, SCHU2670/1-1)
- German Cancer Aid (111917)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- p53, cancer metabolism, metabolic reprogramming, tumor microenvironment, nutrient restriction, anabolic metabolism, p53 deficiency, selective cancer cell killing, oncogenic signalling pathways, tumour suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


